ECO Animal Health Group plc (LON:EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, has announced an update on trading and business progress for the year ending 31 March 2024.
Strong trading from health products globally
Revenue for the fourth quarter and second half of the year ending 31 March 2024, was in line with expectations, driven by continued strong performance of Aivlosin®, the Company’s patented antimicrobial used under veterinary prescription for the treatment of economically important respiratory and gastrointestinal diseases in pigs and poultry.